Share on StockTwits

Exelixis (NASDAQ:EXEL) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 50,541,127 shares, a growth of 6.9% from the July 15th total of 47,267,295 shares, StockRatingsNetwork reports. Currently, 26.7% of the company’s stock are short sold. Based on an average daily trading volume, of 5,754,759 shares, the short-interest ratio is currently 8.8 days.

Shares of Exelixis (NASDAQ:EXEL) traded up 0.48% during mid-day trading on Monday, hitting $4.23. 1,741,823 shares of the company’s stock traded hands. Exelixis has a 1-year low of $3.02 and a 1-year high of $8.41. The stock’s 50-day moving average is $3.76 and its 200-day moving average is $4.65. The company’s market cap is $825.3 million.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.01. The company had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.66 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was down 44.7% on a year-over-year basis. On average, analysts predict that Exelixis will post $-1.54 earnings per share for the current fiscal year.

Exelixis, Inc (NASDAQ:EXEL) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.